Actively Recruiting
Study on the Improvement of Myocardial Microcirculation After Acute Anterior Myocardial Infarction
Led by Harbin Medical University · Updated on 2024-10-18
90
Participants Needed
1
Research Sites
79 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a prospective, single-center, randomized controlled clinical trial. Ninety patients with anterior wall ST-segment elevation myocardial infarction (STEMI) who are planned for primary percutaneous coronary intervention (PCI) within 6 hours of symptom onset will be screened. Patients with inclusion criteria and without exclusion criteria will be randomized into three groups in a 1:1:1 ratio: OCT-guided group, 60 MHz HD-IVUS-guided group, and angiography-guided group after signing the informed consent form. Based on the lesion characteristics detected by imaging in each group, coronary revascularization will be performed for the culprit vessels of myocardial infarction. The TIMI myocardial perfusion frame count (TMPFC) values of the culprit vessels will be recorded immediately after PCI, and secondary prevention medications for myocardial infarction will be administered. Three days after the procedure, a 3.0T cardiac magnetic resonance imaging (MRI) with gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) delayed enhancement (LEG) scan will be conducted to assess the microvascular obstruction (MVO) area. Patients will be followed in the outpatient clinic visit at 1 month (with a window period of XX days) after discharge, and a repeat cardiac MRI will be performed to determine the presence of MVO and the size of the myocardial infarction.
CONDITIONS
Official Title
Study on the Improvement of Myocardial Microcirculation After Acute Anterior Myocardial Infarction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Initial diagnosis of anterior wall ST-segment elevation myocardial infarction with symptom onset within 6 hours
- Planned for primary percutaneous coronary intervention (PCI)
- Signed informed consent from patient or legal representative
- Target lesion is the culprit lesion in native coronary artery with estimated reference vessel diameter between 2.25 mm and 4.0 mm
- Culprit lesion located between the origin of the left anterior descending artery and the second diagonal branch
- After pre-treatment, stenosis in the left anterior descending artery is 90% or less, and TIMI flow grade is 3
You will not qualify if you...
- History of coronary artery bypass grafting (CABG)
- Previous myocardial infarction or PCI
- Received thrombolytic therapy before PCI
- Severe liver or kidney dysfunction, severe valvular heart disease, or chronic obstructive pulmonary disease
- Contraindications to magnetic resonance imaging
- Allergy to gadolinium contrast agents or medications related to devices or procedures
- Expected lifespan less than 12 months
- Pregnant or lactating females
- Other conditions that investigator deems unsuitable for study participation
- Lesions requiring intervention other than the target lesion at baseline surgery
- Left main coronary artery disease with stenosis over 50%
- Diffuse severe calcification over 20 mm or chronic total occlusion in major coronary vessels
- Severe coronary artery tortuosity over 45 degrees or calcification over 270 degrees, or other conditions interfering with intravascular imaging
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The 2nd Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Actively Recruiting
Research Team
X
Xingtao Huang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here